FDA Clears LPCN 2101 IND For Adult Epilepsy Treatment
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders with high unmet medical needs, announced